Compare Novo Nordisk A/S (NVO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Regeneron Pharmaceuticals Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Novo Nordisk A/S is far larger — about 3.1× Regeneron Pharmaceuticals Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | REGN | |
|---|---|---|
Market Cap | $220.53B | $70.47B |
Sector | Health | Health |
52-Week High | $71.70 | $812.27 |
52-Week Low | $35.29 | $545.46 |
Enterprise Value | $239.49B | $64.42B |
Dividend Yield | 3.63% | 0.56% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
